Autoimmune diseases: MIF as a therapeutic target

被引：68
|
作者：
Greven, Dorothee [1 ]
Leng, Lin [2 ]
Bucala, Richard [2 ]
机构：
[1] Univ Amsterdam, Acad Med Ctr, Div Clin Immunol & Rheumatol, NL-1105 AZ Amsterdam, Netherlands
[2] Yale Univ, Rheumatol Sect, New Haven, CT 06510 USA
来源：
EXPERT OPINION ON THERAPEUTIC TARGETS | 2010年 / 14卷 / 03期
关键词：
MIGRATION-INHIBITORY FACTOR; JUVENILE IDIOPATHIC ARTHRITIS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; FACTOR GENE POLYMORPHISM; INNATE IMMUNE-RESPONSES; RHEUMATOID-ARTHRITIS; REGULATORY ROLE; PROINFLAMMATORY FUNCTION; PROMOTER POLYMORPHISMS; CRYSTAL-STRUCTURE;
D O I：
10.1517/14728220903551304
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Areas covered in this review: Our aim is to discuss MIF-directed therapies as a novel therapeutic approach. The review covers literature from the past 10 years. What the reader will gain: MIF inhibition has been shown to be efficacious in many experimental and pre-clinical studies of autoimmune inflammatory diseases. The close regulatory relationship between MIF and glucocorticoids makes therapeutic antagonism of MIF a potential steroid-sparing therapy in patients with refractory autoimmune diseases. Take home message: We expect that MIF antagonism by either small-molecule- or antibody-based approaches will find wide application in the treatment of autoimmune inflammatory diseases. Such therapy also may be informed by the MIF genotype of affected patients.
引用
收藏
页码：253 / 264
页数：12
相关论文
共 50 条
  • [1] Macrophage migration inhibitory Factor (MIF) as a therapeutic target for rheumatoid arthritis and systemic lupus erythematosus
    Bilsborrow, Joshua B.
    Doherty, Edward
    Tilstam, Pathricia V.
    Bucala, Richard
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2019, 23 (09) : 733 - 744
  • [2] Pentraxin 3: A promising therapeutic target for autoimmune diseases
    Wu, Qian
    Cao, Fan
    Tao, Jinhui
    Li, Xiaomei
    Zheng, Song Guo
    Pan, Hai-Feng
    AUTOIMMUNITY REVIEWS, 2020, 19 (12)
  • [3] SIRT1: A Potential Therapeutic Target in Autoimmune Diseases
    Shen, Pan
    Deng, Xuan
    Chen, Zhe
    Ba, Xin
    Qin, Kai
    Huang, Ying
    Huang, Yao
    Li, Tingting
    Yan, Jiahui
    Tu, Shenghao
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [4] TIGIT as a Promising Therapeutic Target in Autoimmune Diseases
    Yue, Chenran
    Gao, Sheng
    Li, Shuting
    Xing, Zhouhang
    Qian, Hengrong
    Hu, Ying
    Wang, Wenqian
    Hua, Chunyan
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [5] Natural Killer Cells: Potential Biomarkers and Therapeutic Target in Autoimmune Diseases?
    Gianchecchi, Elena
    Delfino, Domenico V.
    Fierabracci, Alessandra
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [6] The MicroRNA-326: Autoimmune diseases, diagnostic biomarker, and therapeutic target
    Jadideslam, Golamreza
    Ansarin, Khalil
    Sakhinia, Ebrahim
    Alipour, Shahriar
    Pouremamali, Farhad
    Khabbazi, Alireza
    JOURNAL OF CELLULAR PHYSIOLOGY, 2018, 233 (12) : 9209 - 9222
  • [7] Homocysteine as a trigger and potential therapeutic target for autoimmune diseases
    Hu, Xiao
    Wang, Jie-Bing
    Zhao, Yan
    Fang, Yang
    Chen, Cong
    Ge, Man
    Xu, Yi-Qing
    Gao, Zhao-Xing
    Wang, Hai-Peng
    Wang, Peng
    AUTOIMMUNITY REVIEWS, 2023, 22 (09)
  • [8] Role of MIF and D-DT in immune-inflammatory, autoimmune, and chronic respiratory diseases: from pathogenic factors to therapeutic targets
    Gunther, Sven
    Fagone, Paolo
    Jalce, Gael
    Atanasov, Atanas G.
    Guignabert, Christophe
    Nicoletti, Ferdinando
    DRUG DISCOVERY TODAY, 2019, 24 (02) : 428 - 439
  • [9] The role of MIF in periodontitis: A potential pathogenic driver, biomarker, and therapeutic target
    Fang, Tongfeng
    Liu, Liu
    Song, Dongzhe
    Huang, Dingming
    ORAL DISEASES, 2024, 30 (03) : 921 - 937
  • [10] GM-CSF as a therapeutic target in autoimmune diseases
    Shiomi A.
    Usui T.
    Mimori T.
    Inflammation and Regeneration, 36 (1)
12345